OmniAb, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
March 30, 2023 at 09:14 pm
Share
OmniAb, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported revenue was USD 35.35 million compared to USD 15.28 million a year ago. Net income was USD 6.82 million compared to net loss of USD 3.07 million a year ago. Basic earnings per share from continuing operations was USD 0.07 compared to basic loss per share from continuing operations of USD 0.04 a year ago. Diluted earnings per share from continuing operations was USD 0.07 compared to diluted loss per share from continuing operations of USD 0.04 a year ago.
For the full year, the company reported revenue was USD 59.08 million compared to USD 34.75 million a year ago. Net loss was USD 22.33 million compared to USD 27.04 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.33 a year ago. Diluted loss per share from continuing operations was USD 0.26 compared to USD 0.33 a year ago.
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Companyâs OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
OMNIAB, INC. 
